Biocon Biologics earlier announced a settlement agreement in the United States for a Bmab 1200 launch no later than February 22, 2025
The drugmaker's net profit slipped 26 per cent on-year to Rs 143.8 crore
The HD21 study adds to the body of evidence supporting ADCETRIS as a backbone agent in the treatment of specific lymphomas
Pfizer to discuss regulatory submission with FDA, potentially leading to eighth indication for ADCETRIS
Glenmark Life Sciences will manufacture API in the therapeutic area of urinary anti-spasmodic, to supply to the global innovator
TALZENNA is the first and only PARP inhibitor approved in combination with standard of care XTANDI for mCRPC patients in the European Union
Late-stage Fabhalta development program ongoing in multiple complement-mediated conditions
The inspection of the facility conducted from August 7 to August 11, 2023
The USFDA inspectors issued the observations after a product pre-approval inspection of the biologics facility in Bachupally
The company through its IPO will fetch Rs 1475.26 crore - Rs 1550.59 crore at the lower and upper end of the price band.
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
